Rate this item
(0 votes)

Alona Tal

By Super User 25 April, 2018 3713

Manager of Quality Assurance. Alona joined the Company in 2011 as a Research Associate. As of 2017 she serves as a head of QA department. Alona holds a B.Sc. in Biotechnology from Hadassah Academic College and M.Sc. in Genetics from Hebrew University in Jerusalem.


Last modified on Friday, 27 April 2018 20:04



Treatment strategy designed to use the power of the human immune system to kill tumors and prevent their recurrence.
No requirement for a matched donor or chemotherapy/radiation conditioning prior to treatment.
Innovative technology – proven and non-toxic.
read more

Healthcare professionals

Therapeutic anti-tumor vaccine developed from core break-through technology called the "Mirror Effect™“ which opens a pathway to treating patients with metastatic cancer that have failed all available therapy options.
Elicits a GVT-like mechanism without the GVHD toxicity.
read more


Privately-held Israeli biopharmaceutical company spin out from Hadassah-Hebrew University Medical Center with headquarters in Jerusalem.

Over 200 individual private shareholders and grant support from the Israel Office of the Chief Scientist.
read more